Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
06 mrt 2015 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos reports 2014 financial results
Bericht
Robust clinical programs in inflammation and cystic fibrosis supported by a strong financial position
Key 2014 results:
Group revenues €108m, including €18m from discontinued operations
Group net profit €33m resulting from divestment of service operations
Year-end cash €198m, including €11m in restricted cash
Filgotinib: recruitment completed for phase 2B studies DARWIN 1 and 2; 98% of eligible patients enrolled in long term extension DARWIN 3
Cystic fibrosis program in the clinic
GLPG1205 in Phase 2A study for ulcerative colitis
Datum laatste update: 21 februari 2026